Lymphatic and vascular invasion in oral squamous cell carcinoma: Implications for recurrence and survival in a population-based cohort study.
Adult
Aged
Aged, 80 and over
Analysis of Variance
Blood Vessels
/ pathology
Chemoradiotherapy, Adjuvant
Cohort Studies
Disease-Free Survival
Female
Follow-Up Studies
Germany
Humans
Lymph Nodes
/ pathology
Lymphatic Vessels
/ pathology
Male
Middle Aged
Mouth Neoplasms
/ mortality
Neoplasm Invasiveness
/ pathology
Neoplasm Recurrence, Local
/ mortality
Radiotherapy, Adjuvant
Retrospective Studies
Squamous Cell Carcinoma of Head and Neck
/ mortality
Survival Analysis
Adjuvant therapy
Blood vessel invasion
Lymphatic vessel invasion
Lymphovascular invasion
Oral squamous cell carcinoma
Survival
Journal
Oral oncology
ISSN: 1879-0593
Titre abrégé: Oral Oncol
Pays: England
ID NLM: 9709118
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
20
05
2020
revised:
04
08
2020
accepted:
09
09
2020
pubmed:
9
10
2020
medline:
18
9
2021
entrez:
8
10
2020
Statut:
ppublish
Résumé
Numerous studies analyzed lymphovascular invasion (LVI) in various malignant diseases, however, little is known about the role of lymphatic invasion (LI) as well as vascular invasion (VI) in oral squamous cell carcinoma (OSCC). The aim of this study is to illuminate the role of LI and VI in a population-based cohort study. We retrospectively analyzed 745 primarily resected OSCC patients in Eastern Bavaria for histopathologically verified LI and VI. Overall survival (OS) and recurrence-free survival (RFS) were calculated, whereas analysis was performed by uni- and multivariate statistics. Mean follow-up time was 7.4 years. LI was found in 115 patients (15.4%), VI was diagnosed in 23 cases (3.1%). LI correlated significantly with distinct anatomical sites (p = 0.004), increasing pT-classification (p < 0.001), lymph node involvement (p < 0.001), higher grading (p < 0.001), advanced UICC-stages (p < 0.001) and adjuvant therapies (p < 0.001). Similar results were found for VI. Survival analysis resulted in a significantly decreased five-year OS and RFS in patients with diagnosed LI (OS: 41.1%, RFS: 38.3%) in contrast to LI-negative cases (OS: 66.8%, RFS: 59.7.7%, p < 0.001). Analogous outcomes were seen for patients with VI. Additionally, LI was identified as a predictive parameter, indicating individual patients' response to adjuvant therapies. This population-based cohort study underlines the unfavorable aspect of LI and VI on outcome in OSCC. Including LI and VI in existing staging systems could help to stratify patients' risk for adverse outcome and consecutively determine adjuvant treatment in malignant disease.
Identifiants
pubmed: 33032181
pii: S1368-8375(20)30445-0
doi: 10.1016/j.oraloncology.2020.105009
pii:
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
105009Informations de copyright
Copyright © 2020. Published by Elsevier Ltd.